Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss(1) – Yahoo Finance


Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1
DORVAL, QC, Sept. 20, 2022 /CNW/ – Novartis Pharmaceuticals Canada Inc. and the pan Canadian Pharmaceutical Alliance (pCPA) have successfully concluded negotiations for Luxturna® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.
Inherited retinal dystrophies (IRDs) are a major cause of early onset blindness2. RPE65-mediated IRDs are rare, serious, and progressive conditions that ultimately lead to severe visual impairment and blindness. Prior to the approval of Luxturna®, there were no available pharmacological treatment options for this form of inherited blindness2.
“We are thrilled to have positively completed these negotiations for Luxturna®, one of two pioneering targeted gene therapies Novartis has introduced in Canada for patients and families devastated by rare, debilitating or life-threatening genetic diseases. For all Canadians who urgently need treatment with this innovative therapy, this is an important step to achieve access,” said Andrea Marazzi, Country President, Novartis Canada. “We will continue to work collaboratively with provincial and territorial jurisdictions so that patients whose vision is impaired as a result of a mutation in both copies of the RPE65 gene can have access to Luxturna® through public drug plans as quickly as possible.”
“This type of inherited eye disease affects children and young adults and creates a significant impact on the entire family,” said Doug Earle, President & CEO of Fighting Blindness Canada.
“For the majority, it can lead to complete blindness as cells in the retina, the light sensitive tissue of the eye, gradually stop working, work less effectively, or die2. Having access to a treatment that can help restore sight, can be life-altering for a child or young adult and their family. We encourage the provinces to recognize the hope Luxturna® represents and prioritize access as there are no approved alternative treatments available for these Canadians.”
About RPE65 mutation-associated inherited retinal dystrophy
Mutations in both copies of the RPE65 gene affect approximately 1 in 200,000 people and can lead to blindness3,4. Early in the disease patients can suffer from night blindness (nyctalopia), loss of light sensitivity, loss of peripheral vision, loss of sharpness or clarity of vision, impaired dark adaptation and repetitive uncontrolled movements of the eye (nystagmus)4. Patients with mutations in both copies of the RPE65 gene may be diagnosed, for instance, with subtypes of either retinitis pigmentosa or Leber congenital amaurosis5.
About Novartis in Gene Therapy and Rare Disease 
Novartis is at the forefront of cell and gene therapies designed to halt diseases in their tracks or reverse their progress rather than simply manage symptoms. The company is collaborating on the cell and gene therapy frontier to bring this major leap in personalized medicine to patients with a variety of diseases, including genetic disorders and certain deadly cancers. Cell and gene therapies are grounded in careful research that builds on decades of scientific progress. Following key approvals of cell and gene therapies by health authorities, new treatments are being tested in clinical trials around the world.
About Novartis in Canada
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Over the last 5 years, our average annual research and development investment in Canada was $47 million. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. Novartis is recognized as a Great Place to Work®, ranked among the Top 50 Best Workplaces™ in the country and is proudly named on the 2021 Best Workplaces™ for Women in Canada and Best Workplace™ for Mental Wellness lists. For further information, please consult www.novartis.ca.
About Novartis 
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Luxturna is a registered trademark of Spark Therapeutics Inc., used under license by Novartis Pharmaceuticals Canada Inc.
References
Novartis Pharmaceuticals Canada Inc. Luxturna® (voretigene neparvovec) Product Monograph. April 20, 2022
Patel U BM, de Léséleuc L, et al. Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness. CADTH Issues in Emerging Health Technologies Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016. 2018 (169)
Novartis. Data on file. 2018.
Astuti GD et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. European Journal of Human Genetics 2016; 24: 1071–79.
Morimura H et al. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or Leber congenital amaurosis. Proceedings of the National Academy of Sciences of the USA. 1998; 95: 3088–93.
SOURCE Novartis Pharmaceuticals Canada Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/20/c7657.html
The news sent the shares sharply higher in premarket trading, but they had lost those gains, and more, by early afternoon.
The gene-sequencing company is fighting antitrust regulators on two continents as it seeks to hold on to Grail, which it bought last year.
The company has generated billions in sales from this product alone, although many investors now think this tailwind will soon end, as the demand for coronavirus vaccines could drop substantially starting next year. The company is currently working on another promising vaccine that may not become nearly as successful as Comirnaty, but could generate at least $1 billion in annual sales if approved. Let's look into this program and what it could mean for Pfizer.
A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.'s treatment of patients with certain types of non-small cell lung cancer outweigh the risks. The same day the committee is also set to discuss Pepaxto, Oncopeptides AB' investigational multiple myeloma treatment that received an accelerated approval in early 2021.
As biotech companies take new shots at fatty liver disease, investor skepticism and potential payoffs are high.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy vo
Undaunted by a potential battle with a goliath like Pfizer, Prometheus is developing PRA023, an experimental treatment for inflammatory bowel disease. Prometheus' candidate could eventually generate billions in annual revenue, but it will have to overcome PF-06480605, a similar candidate from Pfizer. Can Prometheus take on Pfizer in the lucrative space for inflammatory bowel disease treatments?
It’s been more than 2.5 years and Americans are still suffering from the long-term effects of COVID-19, otherwise known as Long COVID, and it's forced many out of the labor force.
The vegetable was shown to lower blood sugar levels and cholesterol levels
(Bloomberg) — Bluebird Bio Inc.’s shares fell Monday after US regulators approved its gene therapy for a brain-wasting disease with a warning about cancer risks and under the condition that the drugmaker can show that it works long term.Most Read from BloombergSouthwest Mexico Struck by 7.5 Magnitude Earthquake, Buildings Sway in CapitalHome-Flipper Opendoor Hit With Losses in Echo of Zillow CollapseMark Zuckerberg’s $71 Billion Wealth Wipeout Puts Focus on Meta’s WoesGrand Theft Auto VI Leak I
When should you get a flu shot? And can you get a flu shot at the same time as the Omicron booster? Here’s what experts say.
The regulatory agency cautioned that the practice of misusing nonprescription drugs as part of social-media challenges is unsafe.
The recently passed Inflation Reduction Act contains five new healthcare benefits for retirees. Because Congressional Democrats in the Senate passed the Inflation Reduction Act through the reconciliation process, its healthcare provisions apply only to Medicare, Medicaid and other government programs. Consider … Continue reading → The post Inflation Reduction Act: 5 Ways Retirees Can Save on Healthcare appeared first on SmartAsset Blog.
Few daily rituals hold quite as much importance as brushing your teeth. Besides being a grooming requirement essential for keeping your breath fresh, research has also shown that it can have a significant impact on your long-term health as well. In most cases, the only harm that can come from picking up your toothbrush is the result of doing something wrong during the twice-a-day cleaning ritual. But now, the Food&Drug Administration (FDA) is warning that anyone with certain Colgate toothpastes
While excessive drinking is never a good idea and exercise isn’t a way to reverse the bodily harm that alcohol can cause, there is a workout that may bolster your liver function, according to research. Researchers at the University of Missouri School of Medicine discovered that increased …
The human body has an impressive, innate ability to repair itself throughout the normal wear-and-tear of life. And this is where the magic of protein comes in. There's a reason why nutritionists and health experts consider protein to be an essential part of one's diet. These chains of amino acids play roles in muscle growth, digestion, hormonal regulation, cell repair, and energy production.RELATED: 6 Pumpkin Foods To Stay Away From Right Now"Protein contains the building blocks for muscle and t
Here's where you can find COVID booster vaccines in the Evansville and Henderson areas.
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.
In an interview on "60 Minutes," the president said, "We still have a problem with COVID. We're still doing a lotta work on it. … But the pandemic is over."
Yahoo Finance's Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.

source


Leave a Reply

Your email address will not be published.